The Value of a Simple Tool for the Early Detection of Decompensated Heart Failure in People Over 55 on Réunion Island: A Preliminary Study in Hospitals (DEPIST'IC-RUN)

ConditionHeart Failure
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age55+
SponsorCentre Hospitalier Universitaire de la Réunion

About this trial

The goal of this study is to assess the discriminatory power of a previously developed tool for detecting decompensated heart failure-which includes, in particular, clinical signs-in a population of patients hospitalized in cardiology units in Réunion. The main question it aims to answer is : Would a simple and rapid screening tool for decompensated heart failure help identify a high probability of this condition in a population hospitalized in a cardiology unit in Réunion? This study includes patients aged 55 and older, who reside in Réunion, who were admitted on an unscheduled basis to the cardiology department at the Réunion University Hospital or the Ouest Réunion Hospital, for any reason (whether as an inpatient or in the intensive care unit)

The study is conducted in two phases:

Phase 1: Development of the new e-DELPHI consensus-based screening tool Phase 2: Administration of the Déspist'IC-Run early detection tool for decompensated heart failure and performance of the gold standard cardiology examination (RIPH3)

Eligibility criteria

Qualifiers

Aged 55 and older

Admitted on an unscheduled basis to the cardiology department at the CHU (North and South campuses) and the CHOR for any reason (in general wards or intensive care)

Residents of Réunion

Able to read and write French

Disqualifiers

Who cannot communicate in French

For whom it is impossible to administer the questionnaire

For whom the ETT and/or cardiology consultation are impossible

Who are under guardianship, conservatorship, or judicial protection

Trial design

Treatments tested in this trial

  • Early Detection Questionnaire

Treatment groups

300 Participants
are divided into 1 treatment group

Locations

This trial has no locations